Brief: Amphastar Announces Buyback Of 26% Of The Equity In Its Anp Subsidiary And Spin-Off Its Hanxin Subsidiary

Amphastar Pharmaceuticals,

07/05/2021 21:09

May 7 (Reuters) - Amphastar Pharmaceuticals Inc  AMPH.O :
    * AMPHASTAR ANNOUNCES BUYBACK OF 26% OF THE EQUITY IN ITS
ANP
SUBSIDIARY AND SPIN-OFF ITS HANXIN SUBSIDIARY
    * AMPHASTAR PHARMACEUTICALS INC - ANNOUNCED RESTRUCTURING OF
ITS
CHINESE SUBSIDIARIES, PRIMARILY AMPHASTAR NANJING
PHARMACEUTICALS INC
    * AMPHASTAR PHARMACEUTICALS INC - TOTAL CASH PAYMENT BY
AMPHASTAR
FOR THIS RESTRUCTURING WILL BE APPROXIMATELY $29 MILLION
    * AMPHASTAR PHARMACEUTICALS - EXPECT TRANSACTION TO BE
ACCRETIVE
TO AMPHASTAR'S EPS BY APPROXIMATELY $0.03 PER SHARE IN 2021 AND
$0.12 PER SHARE IN 2022
    * AMPHASTAR PHARMA- SOME OF ANP INVESTORS WILL CONCURRENTLY
INVEST
A PORTION OF THEIR ANP SALE PROCEEDS TO PURCHASE A MAJORITY
OWNERSHIP STAKE IN HANXIN

Source text for Eikon:  ID:nGNX3kstmc 
Further company coverage:  AMPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))